# STAT News

Type: Company

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/stat-news-company
Canonical HTML page: https://getfinancebrief.com/entity/stat-news-company

## Timeline

- **2026-03-25**: Clinical Data Release — Early data for FSHD and DM1 therapies reported by STAT and Endpoints News.
- **2026-03-25**: Options Surge — Traders purchase large volumes of call options following the clinical updates.
- **2026-03-13**: Price Target Update — Brokerages adjust targets, including a raise to $9.00 by some analysts.
- **2026-01-12**: Financial Results — Sarepta files results of operations and financial condition with the SEC.

## Recent coverage (1 stories)

### Bullish Options Surge in Sarepta Therapeutics Amid Promising Rare Disease Data
2026-03-25 19:55:52 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Traders have flooded Sarepta Therapeutics with call options following positive early-stage data for its RNA-based rare disease therapies. This surge in bullish sentiment suggests high market confidence in the company's clinical pipeline expansion beyond its core Duchenne muscular dystrophy franchise.
Full story: https://getfinancebrief.com/story/sarepta-therapeutics-options-volume-surge-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.